FDA grants priority review to Biologics License Application for teplizumab for the delay or prevention of clinical type 1 diabetes in at-risk individuals

In previous studies of newly diagnosed patients, teplizumab, an investigational anti-CD3 monoclonal antibody, demonstrated the ability to preserve beta-cell function, a measure of endogenous insulin production, and correspondingly reduced the need for exogenous insulin use.

Source:

Biospace Inc.